The principal goal of our randomized trial is to compare the efficacy of four different interventions, including conventional diet, conventional diet plus glipizide, conventional diet plus metformin, and a life style intervention with intensive diet and exercise, in preventing the progression of impaired glucose tolerance (IGT) to non-insulin dependent diabetes mellitus (NIDDM). Secondary goals include determining whether the interventions will affect the rate of reversion from IGT to normal glucose tolerance and/or improve cardiovascular risk factors, morbidity, or mortality. IGT prevails in 16% of the 40 to 74 year old U.S. population and is an appropriate target for intervention because IGT is l) a major risk factor for NIDDM which is difficult to treat effectively once it develops and is the cause of significant morbidity and mortality and 2), accompanied by numerous cardiovascular risk factors, morbidity and mortality. The proposal defines selection criteria for the IGT study population that will maximize the expected rate of conversion to NIDDM, empowering the study (75 to 93% power) to detect a 33 to 40% reduction in the hazard rate for development of NIDDM with intensive life-style intervention compared with the conventional diet. The selection criteria include screening for IGT subjects in populations with a high rate of recognized NIDDM (hispanic, black, and family members of NIDDM patients) and further selecting a subset of IGT subjects with a relatively high likelihood of progressing to NIDDM, i.e., obese IGT subjects with glucose levels equal to or greater than the median of the IGT range with OGTT. The experimental interventions have been selected based on 1) demonstrated salutary effects on glycemia and/or cardiovascular risk profile; 2) potential for practical application in the clinical setting;3) absence of frequent or severe side- effects. Investigators and subjects will be masked to treatment assignment except for the life-style intervention. Life-table analyses will be used to compare the cumulative incidences of the principal and secondary outcomes among the treatment groups. In addition, the absolute-level of chronic glycemia, selected lipid and insulin values, and blood pressure will be studied.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Garfield, Sanford A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
de Groot, Mary; Marrero, David; Mele, Lisa et al. (2018) Depressive Symptoms, Antidepressant Medication Use, and Inflammatory Markers in the Diabetes Prevention Program. Psychosom Med 80:167-173
Kim, Catherine; Aroda, Vanita R; Goldberg, Ronald B et al. (2018) Androgens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Program. J Clin Endocrinol Metab 103:486-496
Perreault, L; Pan, Q; Aroda, V R et al. (2017) Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabet Med 34:1747-1755
Herman, William H; Pan, Qing; Edelstein, Sharon L et al. (2017) Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. Diabetes Care 40:1668-1677
Billings, Liana K; Jablonski, Kathleen A; Warner, A Sofia et al. (2017) Variation in Maturity-Onset Diabetes of the Young Genes Influence Response to Interventions for Diabetes Prevention. J Clin Endocrinol Metab 102:2678-2689
Mercader, Josep M; Liao, Rachel G; Bell, Avery D et al. (2017) A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes. Diabetes 66:2903-2914
Aroda, Vanita R; Knowler, William C; Crandall, Jill P et al. (2017) Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia 60:1601-1611
Rockette-Wagner, Bonny; Storti, Kristi L; Dabelea, Dana et al. (2017) Activity and Sedentary Time 10 Years After a Successful Lifestyle Intervention: The Diabetes Prevention Program. Am J Prev Med 52:292-299
Crandall, Jill P; Mather, Kieren; Rajpathak, Swapnil N et al. (2017) Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ Open Diabetes Res Care 5:e000438
Luchsinger, José A; Ma, Yong; Christophi, Costas A et al. (2017) Metformin, Lifestyle Intervention, and Cognition in the Diabetes Prevention Program Outcomes Study. Diabetes Care 40:958-965

Showing the most recent 10 out of 30 publications